Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective
Authors:
Open Access
- 15 May 2025
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 709-718
Abstract
No abstract availableFunding Information
- Eli Lilly and Company
This publication has 25 references indexed in Scilit:
- Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative reviewDigestive and Liver Disease, 2021
- Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at DiagnosisClinical Gastroenterology and Hepatology, 2020
- First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-AnalysisClinical Gastroenterology and Hepatology, 2020
- One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net BenefitPharmacoEconomics, 2019
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2019
- Ulcerative colitisThe Lancet, 2017
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue in Health, 2014
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- Evidence-based dermatology: Number needed to treat and its relation to other risk measuresJournal of the American Academy of Dermatology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005